D
Intellia Therapeutics, Inc. NTLA
$9.52 -$2.80-22.73% NASDAQ
Recommendation
Prev Close
$12.32
Volume
25,413,219
Avg Vol (90D)
6,540,627
Market Cap
$1.32B
Dividend & Yield
--
52-Week Range
$5.90 - $28.25
P/E (TTM)
--
EPS (TTM)
-$4.69
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
7/15/2025 - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.10 EPS
11/8/2025 - MarketBeat
Wells Fargo Lowers PT on Intellia Therapeutics (NTLA), Maintains Rating NTLA Stock News
11/7/2025 - GuruFocus
Q3 2025 Intellia Therapeutics Inc Earnings Call Transcript
11/7/2025 - GuruFocus
Video: Friday Sector Laggards: Semiconductors, Biotechnology Stocks
11/7/2025 - Market News Video
Intellia Therapeutics (NASDAQ:NTLA) Earns Underweight Rating from JPMorgan Chase & Co.
11/7/2025 - Ticker Report
Intellia Therapeutics price target lowered by $5 at RBC Capital, here's why
11/7/2025 - The Fly
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
11/7/2025 - Zacks Investment Research
Intellia Therapeutics (NTLA) Reports Strong Revenue Growth and Solid Financial Position
11/7/2025 - GuruFocus
Stocks Slide To Session Lows As Risk Sentiment Fractures
11/7/2025 - Zero Hedge
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
11/7/2025 - Fool.com Headlines
Intellia Therapeutics price target lowered by $6 at Oppenheimer, here's why
11/7/2025 - The Fly
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
11/7/2025 - TipRanks Financial Blog
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year
11/7/2025 - The Fly
Intellia Therapeutics (NTLA) Shares Plunge After Phase 3 Trial Setback
11/7/2025 - GuruFocus
JP Morgan Downgrades Intellia Therapeutics (NTLA) with Lower Price Target NTLA Stock News
11/7/2025 - GuruFocus
Intellia Therapeutics price target lowered to $4 from $9 at Baird
11/7/2025 - TipRanks Financial Blog
Intellia Therapeutics price target lowered by $5 at Baird, here's why
11/7/2025 - The Fly
Intellia Therapeutics price target lowered by $5 at Wells Fargo, here's why
11/7/2025 - The Fly
Intellia Therapeutics (NTLA) Faces Setback with FDA Hold on Key Trials
11/7/2025 - GuruFocus
Intellia Therapeutics price target lowered by $8 at Citizens JMP, here's why
11/7/2025 - The Fly
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
11/7/2025 - SeekingAlpha
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
11/7/2025 - Seeking Alpha: Transcripts
Intellia Therapeutics price target lowered by $10 at Barclays, here's why
11/7/2025 - The Fly
Analysts Think These Stocks Could More Than Double in Value
5/23/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$52.86M
EBITDA (TTM)
-$501.87M
EBIT (TTM)
-$512.02M
Net Income (TTM)
-$480.19M
Balance Sheet
Total Assets (Q)
$898.89M
Total Debt (Q)
$102.59M
Total Liabilities (Q)
$183.64M
Book Value Per Share (Q)
$6.79
Cash Flow
Cash from Operations (TTM)
-$418.58M
Cash from Investing (TTM)
$345.09M
Cash from Financing (TTM)
$99.16M
Net Change in Cash (TTM)
$25.67M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
2.57
7-Day Total Return
-27.44%
30-Day Total Return
-41.63%
60-Day Total Return
-12.66%
90-Day Total Return
-11.28%
Year to Date Total Return
-22.09%
1-Year Total Return
-40.50%
2-Year Total Return
-67.72%
3-Year Total Return
-80.38%
5-Year Total Return
-66.86%
52-week Low
Apr 07, 2025 - $5.90
52-week High
Oct 20, 2025 - $28.25
Valuation
Market Cap
$1.32B - Small Cap
Enterprise Value
$794.60M
Price/Sales (TTM)
24.18
Price/Book (Q)
1.81
Dividends and Shares
Shares Outstanding
103.73
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.intelliatx.com
Phone Number
857 285 6200
Address
40 Erie Street
Cambridge, MA 02139
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in... more
NASDAQ 11/07/2025 4:00PM Eastern Quotes delayed